Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Gains from Investment Securities (2017 - 2025)

Aclaris Therapeutics has reported Gains from Investment Securities over the past 9 years, most recently at $400000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $400000.0 for Q4 2025, up 91.39% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (up 108.94% YoY), and the annual figure for FY2025 was $11.3 million, up 331.99%.
  • Gains from Investment Securities for Q4 2025 was $400000.0 at Aclaris Therapeutics, down from $5.2 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for ACRS hit a ceiling of $10.6 million in Q1 2025 and a floor of -$26.3 million in Q4 2023.
  • Median Gains from Investment Securities over the past 5 years was $853864.0 (2022), compared with a mean of $593151.1.
  • Peak annual rise in Gains from Investment Securities hit 97978.91% in 2023, while the deepest fall reached 356.95% in 2023.
  • Aclaris Therapeutics' Gains from Investment Securities stood at $2.2 million in 2021, then tumbled by 61.19% to $853864.0 in 2022, then plummeted by 3180.12% to -$26.3 million in 2023, then soared by 100.79% to $209000.0 in 2024, then skyrocketed by 91.39% to $400000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $400000.0 (Q4 2025), $5.2 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.